

Microbiote intestinal et médicaments : une interaction déterminante pour l'efficacité thérapeutique

PARTIE 1



➤ Dr Roland Lawson, MDC, Département de Pharmacologie, Faculté de Pharmacie, Univ de Limoges, France

BIBLIOGRAPHIE

- [1] Norvaisas, P., and Cabreiro, F. (2018). Pharmacology in the age of the holobiont. *Current Opinion in Systems Biology* 10, 34–42. <https://doi.org/10.1016/j.coisb.2018.05.006>.
- [2] Simon, J.-C., Marchesi, J.R., Mougel, C., and Selosse, M.-A. (2019). Host-microbiota interactions: from holobiont theory to analysis. *Microbiome* 7, 5. <https://doi.org/10.1186/s40168-019-0619-4>.
- [3] Le microbiote <https://www.leem.org/le-microbiote>.
- [4] Cresci, G.A., and Bawden, E. (2015). The Gut Microbiome: What we do and don't know. *Nutr Clin Pract* 30, 734–746. <https://doi.org/10.1177/0885433615609899>.
- [5] Zhang, Z., Tang, H., Chen, P., Xie, H., and Tao, Y. (2019). Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome. *Signal Transduct Target Ther* 4, 41. <https://doi.org/10.1038/s41392-019-0074-5>.
- [6] Wang, B., Yao, M., Lv, L., Ling, Z., and Li, L. (2017). The Human Microbiota in Health and Disease. *Engineering* 3, 71–82. <https://doi.org/10.1016/j.eng.2017.01.008>.
- [7] Doestzada, M., Vila, A.V., Zernakova, A., Koonen, D.P.Y., Weersma, R.K., Touw, D.J., Kuipers, F., Wijmenga, C., and Fu, J. (2018). Pharmacomicrobiomics: a novel route towards personalized medicine? *Protein Cell* 9, 432–445. <https://doi.org/10.1007/s13238-018-0547-2>.
- [8] Sharma, A., Buschmann, M.M., and Gilbert, J.A. (2019). Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response? *Clinical Pharmacology & Therapeutics* 106, 317–328. <https://doi.org/10.1002/cpt.1437>.
- [9] Aziz, R.K., Hegazy, S.M., Yasser, R., Rizkallah, M.R., and ElRakaiby, M.T. (2018). Drug pharmacomicrobiomics and toxicomicrobiomics: from scattered reports to systematic studies of drug-microbiome interactions. *Expert Opin Drug Metab Toxicol* 14, 1043–1055. <https://doi.org/10.1080/17425255.2018.1530216>.
- [10] Zhao, Q., Chen, Y., Huang, W., Zhou, H., and Zhang, W. (2023). Drug-microbiota interactions: an emerging priority for precision medicine. *Signal Transduct Target Ther* 8, 386. <https://doi.org/10.1038/s41392-023-01619-w>.
- [11] Lange, K., Buerger, M., Stallmach, A., and Bruns, T. (2016). Effects of Antibiotics on Gut Microbiota. *Dig Dis* 34, 260–268. <https://doi.org/10.1159/000443360>.
- [12] Maier, L., Pruteanu, M., Kuhn, M., Zeller, G., Telzerow, A., Anderson, E.E., Brochado, A.R., Fernandez, K.C., Dose, H., Mori, H., et al. (2018). Extensive impact of non-antibiotic drugs on human gut bacteria. *Nature* 555, 623–628. <https://doi.org/10.1038/nature25979>.
- [13] Dogra, S.K., Doré, J., and Damak, S. (2020). Gut Microbiota Resilience: Definition, Link to Health and Strategies for Intervention. *Front Microbiol* 11, 572921. <https://doi.org/10.3389/fmicb.2020.572921>.
- [14] Kinashi, Y., and Hase, K. (2021). Partners in Leaky Gut Syndrome: Intestinal Dysbiosis and Autoimmunity. *Front Immunol* 12, 673708. <https://doi.org/10.3389/fimmu.2021.673708>.
- [15] Michielan, A., and D'Inca, R. (2015). Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut. *Mediators Inflamm* 2015, 628157. <https://doi.org/10.1155/2015/628157>.
- [16] Zhou, Z., Sun, B., Yu, D., and Zhu, C. (2022). Gut Microbiota: An Important Player in Type 2 Diabetes Mellitus. *Front Cell Infect Microbiol* 12, 834485. <https://doi.org/10.3389/fcimb.2022.834485>.
- [17] Sharon, G., Sampson, T.R., Geschwind, D.H., and Mazmanian, S.K. (2016). The Central Nervous System and the Gut Microbiome. *Cell* 167, 915–932. <https://doi.org/10.1016/j.cell.2016.10.027>.
- [18] Tuteja, S., and Ferguson, J.F. (2019). The Gut Microbiome and Response to Cardiovascular Drugs. *Circ Genom Precis Med* 12, 421–429. <https://doi.org/10.1161/CIRCGEN.119.002314>.
- [19] Wang, S., Ju, D., and Zeng, X. (2024). Mechanisms and Clinical Implications of Human Gut Microbiota-Drug Interactions in the Precision Medicine Era. *Biomedicines* 12, 194. <https://doi.org/10.3390/biomedicines12010194>.
- [20] Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D.P., Pfirschke, C., Engblom, C., Pittet, M.J., et al. (2013). The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. *Science* 342, 971–976. <https://doi.org/10.1126/science.1240537>.
- [21] Daillère, R., Vétizou, M., Waldschmitt, N., Yamazaki, T., Isnard, C., Poirier-Colame, V., Duong, C.P.M., Flament, C., Lepage, P., Roberti, M.P., et al. (2016). Enterococcus hirae and *Barnesiella* intestinalis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. *Immunity* 45, 931–943. <https://doi.org/10.1016/j.immuni.2016.09.009>.
- [22] Takasuna, K., Hagiwara, T., Hirohashi, M., Kato, M., Nomura, M., Nagai, E., Yokoi, T., and Kamataki, T. (1996). Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. *Cancer Res* 56, 3752–3757.
- [23] Cheng, K.-W., Tseng, C.-H., Tzeng, C.-C., Leu, Y.-L., Cheng, T.-C., Wang, J.-Y., Chang, J.-M., Lu, Y.-C., Cheng, C.-M., Chen, I.-J., et al. (2019). Pharmacological inhibition of bacterial β -glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo. *Pharmacological Research* 139, 41–49. <https://doi.org/10.1016/j.phrs.2018.10.029>.
- [24] Kong, R., Liu, T., Zhu, X., Ahmad, S., Williams, A.L., Phan, A.T., Zhao, H., Scott, J.E., Yeh, L.-A., and Wong, S.T.C. (2014). Old drug new use—amoxapine and its metabolites as potent bacterial β -glucuronidase inhibitors for alleviating cancer drug toxicity. *Clin. Cancer Res.* 20, 3521–3530. <https://doi.org/10.1158/1078-0432.CCR-14-0395>.
- [25] Jorgensen, A.L., FitzGerald, R.J., Oyee, J., Pirmohamed, M., and Williamson, P.R. (2012). Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis. *PLoS One* 7, e44064. <https://doi.org/10.1371/journal.pone.0044064>.
- [26] Wang, L., Liu, L., Liu, X., Xiang, M., Zhou, L., Huang, C., Shen, Z., and Miao, L. (2020). The gut microbes, *Enterococcus* and *Escherichia-Shigella*, affect the responses of heart valve replacement patients to the anticoagulant warfarin. *Pharmacol Res* 159, 104979. <https://doi.org/10.1016/j.phrs.2020.104979>.
- [27] Haider, H.J., Seim, K.L., Balskus, E.P., and Turnbaugh, P.J. (2014). Mechanistic insight into digoxin inactivation by *Escherichia coli* augments our understanding of its pharmacokinetics. *Gut Microbes* 5, 233–238. <https://doi.org/10.4161/gmic.27915>.
- [28] Maini Rekdal, V., Bess, E.N., Bisanz, J.E., Turnbaugh, P.J., and Balskus, E.P. (2019). Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. *Science* 364, eaau6323. <https://doi.org/10.1126/science.aau6323>.
- [29] Jameson, K.G., and Hsiao, E.Y. (2019). A novel pathway for microbial metabolism of Levodopa. *Nat Med* 25, 1195–1197. <https://doi.org/10.1038/s41591-019-0544-x>.
- [30] Scher, J.U., Nayak, R.R., Ubeda, C., Turnbaugh, P.J., and Abramson, S.B. (2020). Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response. *Nat Rev Rheumatol* 16, 282–292. <https://doi.org/10.1038/s41584-020-0395-3>.
- [31] Jackson, M.A., Goodrich, J.K., Maxam, M.-E., Freedberg, D.E., Abrams, J.A., Poole, A.C., Sutter, J.L., Welter, D., Ley, R.E., Bell, J.T., et al. (2016). Proton pump inhibitors alter the composition of the gut microbiota. *Gut* 65, 749–756. <https://doi.org/10.1136/gutjnl-2015-310861>.
- [32] Imhann, F., Bonder, M.J., Vich Vila, A., Fu, J., Mujagic, Z., Vork, L., Tigchelaar, E.F., Jankipersadsing, S.A., Cenit, M.C., Harmsen, H.J.M., et al. (2016). Proton pump inhibitors affect the gut microbiome. *Gut* 65, 740–748. <https://doi.org/10.1136/gutjnl-2015-310376>.
- [33] Stark, C.M., Susi, A., Emerick, J., and Nyland, C.M. (2019). Antibiotic and acid-suppression medications during early childhood are associated with obesity. *Gut* 68, 62–69. <https://doi.org/10.1136/gutjnl-2017-314971>.